Search - tctmd.com

Displaying 441 - 460 of 585

Sort: Relevancy | Date

Presentation TCT 2016

Poland Presents: Treatment Options - Should Severe Coronary Artery Disease Be Treated Prior, During, or After TAVR (and in a Single or Staged Procedure)?

Presenter: Eric Van Belle, Jochen Wöhrle, Dariusz Dudek

October 30, 2016

Presentation TCT 2016

Introduction and Session Objectives

Presenter: Eric Van Belle, Jochen Wöhrle

October 30, 2016

Presentation TCT 2016

The Evolution of Therapies for Coronary Artery Disease and Valve Disorders in My Lifetime

Presenter: A. Pieter Kappetein

October 30, 2016

Presentation TCT 2016

Coronary Artery Disease: Pathology and Pathogenesis

Presenter: Peter Barlis, Grzegorz L. Kaluza

October 29, 2016

News Conference News TCT 2016

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

Michael O'Riordan

October 29, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? No Cell Works. Genes are the Answer.

Presenter: Nabil Dib, Philippe Menasché, Marc S. Penn

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiac Progenitor Cells Are the Only One!

Presenter: Nabil Dib, Philippe Menasché, Timothy D. Henry

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Combination of Cells for Additive Effects: This Is the Key!

Presenter: Nabil Dib, Philippe Menasché, Jay H Traverse

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiopoietic Commitment Is the Key!

Presenter: Nabil Dib, Philippe Menasché, Amit Patel

October 15, 2015

Presentation TCT 2015

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Roxana Mehran

October 14, 2015

Presentation TCT 2015

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Deepak L. Bhatt

October 14, 2015

Presentation TCT 2015

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Pascal Vranckx, Renato D. Lopes

October 14, 2015

Presentation TCT 2015

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

Presenter: Pascal Vranckx, Freek W.A. Verheugt

October 14, 2015

Presentation TCT 2015

LEADERS FREE: A Prospective, Double-blind Randomized Trial of a Polymer-Free Biolimus-Eluting Stent Versus Bare Metal Stents in Patients With Coronary Artery Disease at High Risk for Bleeding

Presenter: Cindy L. Grines, Philip M. Urban

October 14, 2015

Presentation TCT 2015

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

Presenter: Cindy L. Grines, Upendra Kaul

October 14, 2015

Presentation TCT 2015

TWENTE: A Prospective Randomized Trial of a Durable-Polymer Zotarolimus-Eluting Stent Versus a Durable-Polymer Everolimus-Eluting Stent in Patients With Coronary Artery Disease Five-Year Outcomes

Presenter: Bernard J. Gersh, Thomas F. Luscher, Clemens von Birgelen

October 14, 2015

Presentation TCT 2015

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

Presenter: Upendra Kaul

October 14, 2015

Presentation TCT 2015

LEADERS FREE: A Prospective, Double-blind Randomized Trial of a Polymer-Free Biolimus-Eluting Stent vs BMS in Patients With Coronary Artery Disease at High Risk for Bleeding

Presenter: Philip M. Urban

October 14, 2015

Presentation TCT 2015

TCT 48: Early Vascular Responses to Everolimus-Eluting Cobalt-Chromium Stent for the Treatment of Stable Coronary Artery Disease The Results of MECHANISM Elective 1-Month OCT Follow-up Cohort

Presenter: Stephan Achenbach, Marc D. Feldman, Toshiro Shinke

October 13, 2015

Advertisement

Poland Presents: Treatment Options - Should Severe Coronary Artery Disease Be Treated Prior, During, or After TAVR (and in a Single or Staged Procedure)?

Introduction and Session Objectives

The Evolution of Therapies for Coronary Artery Disease and Valve Disorders in My Lifetime

Coronary Artery Disease: Pathology and Pathogenesis

YELLOW II: Improved Cholesterol Efflux Linked to Plaque Stabilization in Statin-Treated Patients

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? No Cell Works. Genes are the Answer.

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiac Progenitor Cells Are the Only One!

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Combination of Cells for Additive Effects: This Is the Key!

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiopoietic Commitment Is the Key!

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

LEADERS FREE: A Prospective, Double-blind Randomized Trial of a Polymer-Free Biolimus-Eluting Stent Versus Bare Metal Stents in Patients With Coronary Artery Disease at High Risk for Bleeding

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

TWENTE: A Prospective Randomized Trial of a Durable-Polymer Zotarolimus-Eluting Stent Versus a Durable-Polymer Everolimus-Eluting Stent in Patients With Coronary Artery Disease Five-Year Outcomes

TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease

LEADERS FREE: A Prospective, Double-blind Randomized Trial of a Polymer-Free Biolimus-Eluting Stent vs BMS in Patients With Coronary Artery Disease at High Risk for Bleeding

TCT 48: Early Vascular Responses to Everolimus-Eluting Cobalt-Chromium Stent for the Treatment of Stable Coronary Artery Disease The Results of MECHANISM Elective 1-Month OCT Follow-up Cohort

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content